These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 30231365)
1. National Cancer Institute Programmatic Collaboration for Investigational Radiopharmaceuticals. Kunos CA; Capala J Am Soc Clin Oncol Educ Book; 2018 May; 38():488-494. PubMed ID: 30231365 [TBL] [Abstract][Full Text] [Related]
2. National Cancer Institute support for targeted alpha-emitter therapy. Hong JA; Brechbiel M; Buchsbaum J; Canaria CA; Coleman CN; Escorcia FE; Espey M; Kunos C; Lin F; Narayanan D; Capala J Eur J Nucl Med Mol Imaging; 2021 Dec; 49(1):64-72. PubMed ID: 34378064 [TBL] [Abstract][Full Text] [Related]
4. Radiopharmaceutical Chemistry and Drug Development-What's Changed? Kunos CA; Mankoff DA; Schultz MK; Graves SA; Pryma DA Semin Radiat Oncol; 2021 Jan; 31(1):3-11. PubMed ID: 33246634 [TBL] [Abstract][Full Text] [Related]
5. Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy. Roncali E; Capala J; Benedict SH; Akabani G; Bednarz B; Bhadrasain V; Bolch WE; Buchsbaum JC; Coleman NC; Dewaraja YK; Frey E; Ghaly M; Grudzinski J; Hobbs RF; Howell RW; Humm JL; Kunos CA; Larson S; Lin FI; Madsen M; Mirzadeh S; Morse D; Pryma D; Sgouros G; St James S; Wahl RL; Xiao Y; Zanzonico P; Zukotynski K J Nucl Med; 2021 Aug; 62(8):1133-1139. PubMed ID: 33277396 [TBL] [Abstract][Full Text] [Related]
6. Advancing Targeted Radionuclide Therapy Through the National Cancer Institute's Small Business Innovation Research Pathway. Zakeri K; Narayanan D; Evans G; Prasanna P; Buchsbaum JC; Vikram B; Capala J J Nucl Med; 2019 Jan; 60(1):41-49. PubMed ID: 30030338 [TBL] [Abstract][Full Text] [Related]
7. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute. Christian MC; Pluda JM; Ho PT; Arbuck SG; Murgo AJ; Sausville EA Semin Oncol; 1997 Apr; 24(2):219-40. PubMed ID: 9129691 [TBL] [Abstract][Full Text] [Related]
8. National Cancer Institute Formulary: A Public-Private Partnership Providing Investigators Access to Investigational Anticancer Agents. Cristofaro JV; Ansher SS; Zwiebel JA; Ivy P; Conley B; Abrams JS; Doroshow JH Clin Pharmacol Ther; 2017 May; 101(5):616-618. PubMed ID: 27981567 [TBL] [Abstract][Full Text] [Related]
9. Leveraging National Cancer Institute Programmatic Collaboration for Single Radiopharmaceutical Drug Master Files. Kunos CA; Capala J; Ivy SP Front Oncol; 2019; 9():573. PubMed ID: 31316916 [TBL] [Abstract][Full Text] [Related]
10. The National Cancer Institute: cancer drug discovery and development program. Grever MR; Schepartz SA; Chabner BA Semin Oncol; 1992 Dec; 19(6):622-38. PubMed ID: 1462164 [TBL] [Abstract][Full Text] [Related]
11. Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration. Takebe N; Ahmed MM; Vikram B; Bernhard EJ; Zwiebel J; Norman Coleman C; Kunos CA Semin Radiat Oncol; 2016 Oct; 26(4):271-80. PubMed ID: 27619249 [TBL] [Abstract][Full Text] [Related]
12. Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy. Divgi C; Carrasquillo JA; Meredith R; Seo Y; Frey EC; Bolch WE; Zimmerman BE; Akabani G; Jacobson DA; Brown B; Davern SM; Hobbs RF; Humm J; Moros EG; Morse D; Papineni R; Zanzonico P; Benedict SH; Sgouros G Int J Radiat Oncol Biol Phys; 2021 Mar; 109(4):905-912. PubMed ID: 33309909 [TBL] [Abstract][Full Text] [Related]
13. Molecular imaging news from NCI and the Cancer Imaging Program. Croft BY J Nucl Med; 2009 Mar; 50(3):15N. PubMed ID: 19258252 [No Abstract] [Full Text] [Related]
14. The NCI All Ireland Cancer Conference. Johnston PG; Daly PA; Liu E Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862 [TBL] [Abstract][Full Text] [Related]
15. Learning from exceptional drug responders. Mullard A Nat Rev Drug Discov; 2014 Jun; 13(6):401-2. PubMed ID: 24875081 [No Abstract] [Full Text] [Related]
16. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH. Coyne GO; Takebe N; Chen AP Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823 [TBL] [Abstract][Full Text] [Related]
17. Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Seymour L; Groshen S; Rosner GL; Sullivan DM; Spriggs DR; Reeves S; Gravell A; Ivy SP; Ratain MJ Clin Cancer Res; 2015 Nov; 21(22):5057-63. PubMed ID: 26567365 [TBL] [Abstract][Full Text] [Related]
18. Dosimetry and Radiobiology of Alpha-Particle Emitting Radionuclides. Sgouros G; Hobbs R; Josefsson A Curr Radiopharm; 2018; 11(3):209-214. PubMed ID: 29697036 [TBL] [Abstract][Full Text] [Related]
19. Radiopharmaceuticals for Relapsed or Refractory Leukemias. Kunos CA; Capala J; Ivy SP Front Oncol; 2019; 9():97. PubMed ID: 30859091 [TBL] [Abstract][Full Text] [Related]
20. Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN). Massett HA; Mishkin G; Moscow JA; Gravell A; Steketee M; Kruhm M; Han SH; Barry B; Montello M; Zwiebel J; Abrams JS; Doroshow JH; Ivy SP Clin Cancer Res; 2019 Dec; 25(23):6925-6931. PubMed ID: 31439585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]